Matthew K. Fust - 07 Jun 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
Director
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
07 Jun 2023
Net transactions value
-$171,006
Form type
4
Filing time
09 Jun 2023, 14:32:21 UTC
Previous filing
02 Jun 2023
Next filing
21 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Award $0 +3,860 +15% $0.000000 30,355 07 Jun 2023 Direct F1
transaction RARE Common Stock Disposed to Issuer $171,006 -3,300 -11% $51.82 27,055 07 Jun 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RARE Stock Option (Right to Buy) Award $0 +7,110 $0.000000 7,110 07 Jun 2023 Common Stock 7,110 $51.82 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024.
F2 Shares were acquired upon the vesting of a previously reported RSU and were disposed of to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person.
F3 The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024.